Recce Pharmaceuticals Ltd. (AU:RCE)
ASX:RCE
Want to see AU:RCE full AI Analyst Report?
RCE Stock Chart & Stats
AU$0.41
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.41
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.28 - AU$0.73
Previous CloseN/A
Volume21.12K
Average Volume (3M)154.69K
Market Cap
AU$153.27M
Enterprise ValueAU$164.16M
Total Cash (Recent Filing)AU$602.99K
Total Debt (Recent Filing)AU$11.26M
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding289,183,400
10 Day Avg. Volume112,630
30 Day Avg. Volume154,688
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)-22.52
Price to Sales (P/S)9.15
P/FCF Ratio-3.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)AU$4.25M
Bulls Say, Bears Say
Bulls Say
Platform-based Anti-infective R&DRecce’s core business is a platform for synthetic polymer antibiotics and anti-infective therapies centered on clinical validation (eg RECCE 327). A platform approach creates multiple program optionality and long-term upside if clinical/regulatory milestones are met, reducing reliance on a single asset and aligning with structural demand for new antibiotics against resistant infections.
Improving Free Cash Flow TrendsA 51.97% increase in free cash flow and FCF roughly in line with net income indicate improving cash conversion. For a clinical-stage biotech this durable improvement helps extend the R&D runway, supports ongoing trial spend without immediate commercialization, and reduces near-term dependence on dilutive financing if sustained.
Positive Return On EquityDespite balance sheet stress, a 7.02% ROE signals some effectiveness in generating returns from shareholder capital. This suggests operational efficiency in deploying available equity into R&D and clinical progress, which is meaningful for a development-stage company where demonstrating capital productivity matters to long-term investors and partners.
Bears Say
Declining RevenueA 21.73% revenue decline is a durable headwind for a company lacking commercial products; lower top-line receipts reduce internal funding capacity for trials and regulatory work. Persisting revenue deterioration increases reliance on external capital and raises execution risk across multi-stage clinical programs.
Severely Negative Profitability MarginsExtremely negative net and EBIT margins reflect losses far exceeding revenue, typical for development-stage biotech but problematic if persistent. Such structural negative profitability necessitates recurrent financing, can dilute shareholders, and limits reinvestment capacity absent material clinical or commercial progress.
Negative Equity And High LeverageA negative equity position with a debt-to-equity of -3.53 signals solvency and leverage concerns that materially constrain financial flexibility. This structural weakness can complicate partnering, increase cost of capital, and elevate default or restructuring risk if operating losses persist and financing access tightens.
Recce Pharmaceuticals Ltd. News
RCE FAQ
What was Recce Pharmaceuticals Ltd.’s price range in the past 12 months?
Recce Pharmaceuticals Ltd. lowest share price was AU$0.28 and its highest was AU$0.73 in the past 12 months.
What is Recce Pharmaceuticals Ltd.’s market cap?
Recce Pharmaceuticals Ltd.’s market cap is AU$153.27M.
When is Recce Pharmaceuticals Ltd.’s upcoming earnings report date?
Recce Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 124 days.
How were Recce Pharmaceuticals Ltd.’s earnings last quarter?
Recce Pharmaceuticals Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.057 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.057.
Is Recce Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Recce Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Recce Pharmaceuticals Ltd. pay dividends?
Recce Pharmaceuticals Ltd. does not currently pay dividends.
What is Recce Pharmaceuticals Ltd.’s EPS estimate?
Recce Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Recce Pharmaceuticals Ltd. have?
Recce Pharmaceuticals Ltd. has 289,183,400 shares outstanding.
What happened to Recce Pharmaceuticals Ltd.’s price movement after its last earnings report?
Recce Pharmaceuticals Ltd. reported an EPS of -AU$0.057 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.917%.
Which hedge fund is a major shareholder of Recce Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:RCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Recce Pharmaceuticals Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.63%
12-Months-Change
Fundamentals
Return on Equity
279.21%
Trailing 12-Months
Asset Growth
-51.48%
Trailing 12-Months
Company Description
Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd. (RCE) is a biotechnology company focused on the development and commercialization of innovative anti-infective therapies. The company specializes in creating synthetic polymers to combat serious infections, particularly those caused by antibiotic-resistant bacteria. Recce's lead product candidate, RECCE 327, is designed to treat a range of infections, including sepsis, and is positioned to address the growing global health challenge of antibiotic resistance.
Technical Analysis
Amplia Therapeutics
―
Imugene
―
Alterity Therapeutics
―
Prescient Therapeutics Limited
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---